<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04077905</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC-DMS-HLH-01</org_study_id>
    <nct_id>NCT04077905</nct_id>
  </id_info>
  <brief_title>Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis.</brief_title>
  <official_title>A Prospective Study on the Modified DEP Regimen Induction Therapy in Lymphoma Induced Hemophagocytic Lymphohistiocytosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Friendship Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aimed to investigate the efficacy and safety of pegylated liposomal doxorubicin
      together with etoposide and methylprednisolone as a induction therapy for lymphoma induced
      hemophagocytic lymphohistiocytosis.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 31, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response rate</measure>
    <time_frame>Time Frame: 1 years</time_frame>
    <description>complete response (CR) and partial response (PR) rates</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response rate of lymphoma</measure>
    <time_frame>Time Frame: 1 years</time_frame>
    <description>complete response (CR) and partial response (PR) rates, using the standard response criteria (Cheson and al.)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Time Frame: 1 years</time_frame>
    <description>from date of inclusion to date of progression, relapse, or death from any cause Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Time Frame: 1 years</time_frame>
    <description>from the date of inclusion to date of death, irrespective of cause Adverse Events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Time Frame: 1 years</time_frame>
    <description>any unfavorable and unintended sign , symptom, or disease temporally associated with the use of a medical treatment or procedure that may or may not be considered related to the medical treatment or procedure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hemophagocytic Lymphohistiocytosis</condition>
  <arm_group>
    <arm_group_label>DEP regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>pegylated liposomal doxorubicin, etoposide and methylprednisolone administered in 2 week cycles for 2 cycles</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pegylated liposomal doxorubicin</intervention_name>
    <description>35mg/m² ivgtt on day 1</description>
    <arm_group_label>DEP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Etoposide</intervention_name>
    <description>100mg/m² ivgtt on day 1</description>
    <arm_group_label>DEP regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methylprednisolone</intervention_name>
    <description>2 mg/kg ivgtt or PO days 1 to 3, 0.75 mg/kg ivgtt or PO days 4 to 7, 0.25 mg/kg ivgtt or PO days 8 to 10, 0. 1 mg/kg ivgtt or PO days 11 to 14,</description>
    <arm_group_label>DEP regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1.Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.

          -  2.Patients were older than 2 years of age.

          -  3.Estimated survival time ≥ 1 week.

          -  4.Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive
             tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index &gt;250.

          -  5.sign informed consent.

        Exclusion Criteria:

          -  1.Heart function above grade II (NYHA).

          -  2.Accumulated dose of doxorubicin above 400mg/m2 、epirubicin above
             750mg/m2、pirarubicin above 800mg/m2 or the patients treated with anthracycline induced
             cardiovascular disease.

          -  3.Pregnancy or lactating Women.

          -  4.Allergic to pegylated liposomal doxorubicin or etoposide.

          -  5.Active bleeding of the internal organs.

          -  6.HIV antibody positivity.

          -  7.Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable),
             acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody
             positivity, HCV RNA negative acceptable).

          -  8.Participate in other clinical research at the same time.

          -  9.The researchers considered that patients are not suitable for the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Zhao Wang, PHD</last_name>
    <phone>86-1063139862</phone>
    <email>catenny@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zhao Wang, PHD</last_name>
      <phone>86-63139862</phone>
      <email>catenny@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>August 31, 2019</study_first_submitted>
  <study_first_submitted_qc>August 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 4, 2019</study_first_posted>
  <last_update_submitted>September 4, 2019</last_update_submitted>
  <last_update_submitted_qc>September 4, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Friendship Hospital</investigator_affiliation>
    <investigator_full_name>Zhao Wang</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>pegylated liposomal doxorubicin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphohistiocytosis, Hemophagocytic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

